Patents by Inventor Hartmut Rehwinkel

Hartmut Rehwinkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINEDIONE DERIVATIVES
    Publication number: 20220411381
    Abstract: The present invention covers pyrimidinedione derivatives of general formula (I): (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 29, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Lea Aurelie BOUCHE, Stefan KAULFUSS, Katja ZIMMERMANN, Hartmut REHWINKEL, Roland NEUHAUS, Roman HILLIG, Duy NGUYEN, Judith GÜNTHER, Adelaide Clara FARIA ALVARES DE LEMOS
  • Fused imidazoles as mIDH1 inhibitors
    Patent number: 10919862
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 16, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Ingo Hartung, Hartmut Rehwinkel, Duy Nguyen, Ludwig Zorn, Petra Helfrich, Katja Zimmermann, Roland Neuhaus
  • Benzimidazol-2-amines as mIDH1 inhibitors
    Patent number: 10442772
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 15, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20190062285
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 16, 2018
    Publication date: February 28, 2019
    Inventors: Hartmut REHWINKEL, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
    Patent number: 10137110
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Rehwinkel, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney, Gianna Toschi
  • Benzimidazol-2-amines as MIDH1 inhibitors
    Patent number: 10138226
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: November 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Rehwinkel, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuß, Roland Neuhaus
  • FUSED IMIDAZOLES AS MIDH1 INHIBITORS
    Publication number: 20180215717
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Ingo HARTUNG, Hartmut REHWINKEL, Duy NGUYEN, Ludwig ZORN, Petra HELFRICH, Katja ZIMMERMANN, Roland NEUHAUS
  • Benzimidazol-2-amines as mIDH1 inhibitors
    Patent number: 9957235
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 1, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Benzimidazol-2-amines as MIDH1 inhibitors
    Patent number: 9951027
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: April 24, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Holger Siebeneicher, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Sven Ring, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170320861
    Abstract: The present invention relates to benzim-idazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 9, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut REHWINKEL, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUß, Roland NEUHAUS
  • 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS
    Publication number: 20170319549
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 21, 2015
    Publication date: November 9, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut REHWINKEL, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY, Gianna TOSCHI
  • Phenyl and benzodioxinyl substituted indazoles derivatives
    Patent number: 9738632
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 22, 2017
    Assignees: AstraZeneca AB, Bayer Pharma Aktiengesellschaft
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepisto, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170197921
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Olaf PANKNIN, Sven RING, Sonja ANLAUF, Holger SIEBENEICHER, Duy NGUYEN, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170197922
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Holger SIEBENEICHER, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Sven RING, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS
  • Imidazopyridazines as Akt kinase inhibitors
    Patent number: 9604989
    Abstract: The present invention relates to a method for the treatment of a cancer that is sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I)
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: March 28, 2017
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Hans Briem, Ulf Bömer
  • Phenyl and benzodioxinyl substituted indazoles derivatives
    Publication number: 20170081315
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepisto, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Phenyl and benzodioxinyl substituted indazoles derivatives
    Patent number: 9512110
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 6, 2016
    Assignees: AstraZeneca AB, Bayer Pharma Aktiengesellschaft
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Substituted pyrazolopyrimidines as Akt kinase inhibitors
    Patent number: 9370517
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: June 21, 2016
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesselschaft
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Ulf Bömer
  • Substituted imidazopyrazines as Akt kinase inhibitors
    Patent number: 9260435
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: February 16, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Ulf Bömer
  • 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
    Patent number: RE47047
    Abstract: The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: September 18, 2018
    Assignees: ASTRAZENECA AB, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Markus Berger, Hartmut Rehwinkel, Thomas Zollner, Ekkehard May, Jorma Hassfeld, Heike Schaecke